**Signalization through the αβ T cell receptor (TCR) is a crucial determinant** of T-cell fate and can induce two opposite outcomes during thymocyte development: cell death or survival and differentiation. To date, the role played by T-cell receptor in the oncogenic transformation of developing T cells remains unclear. Here we show that human primary T-cell acute lymphoblastic leukemias expressing an αβ T cell receptor are frequently deficient for phosphatase and tensin homolog protein (PTEN), and fail to respond strongly to T-cell receptor activation. Using Pten-deficient T-cell acute lymphoblastic leukemia mouse models, we confirm that T-cell receptor signaling is involved in leukemogenesis. We show that abrogation of T-cell receptor expression accelerated tumor onset, while enforced expression of a fit transgenic T-cell receptor led to the development of T-cell receptor-negative lymphoma and delayed tumorigenesis. We further demonstrate that pre-tumoral Pten-deficient thymocytes harboring fit T-cell receptors undergo early clonal deletion, thus preventing their malignant transformation, while cells with unfit T-cell receptors that should normally be deleted during positive selection, pass selection and develop T-cell acute lymphoblastic leukemias. Altogether, our data show that fit T-cell receptor signaling suppresses tumor development mediated by Pten loss-of-function and point towards a role of Pten in positive selection.

**Introduction**

Thymopoiesis aims to create a repertoire of mature T cells equipped with a diverse array of functional αβ or γδ T-cell receptors (TCR) able to recognize the broadest possible range of foreign antigens. This large receptor diversity is mainly due to the V(D)J recombination process, in which few of a large pool of V, D and J gene segments are somatically rearranged with imprecise joining. The price to pay for this strategy of random generation of diversity is the creation of a high load of CD4+ CD8+ DP cortical thymocytes bearing no, or “unfit” receptors, i.e. displaying a too low or too high affinity for self peptide-major histocompatibility complex (p-MHC), and which will have to be eliminated through death by neglect (>90% thymocytes) and negative selection ([Online Supplementary Figure S1A](#)). Only the small pool of thymocytes expressing TCR with intermediate affinity and/or avidity for p-MHC (denoted here as fit TCR) will be induced to further differentiate into mature CD4+ or CD8+ SP thymocytes, a transition known as positive selection. Therefore, TCR signaling can induce two opposite outcomes during thymocyte development: cell death or survival and differentiation.

Somatic rearrangement, proliferation and selection provide a propitious environment for major derailments of thymocyte ontogeny. T-cell acute lymphoblastic leukemias (T-ALL) are malignant proliferation of such T-cell progenitors abnormally arrested at various stages of their maturation process ([Online Supplementary Figure S1B](#)). They constitute a particularly heterogeneous group of diseases, resulting...
from a large array of genetic and epigenetic alterations in oncogenes and tumor suppressors. A wealth of information has emerged from recent pan-(epi)genomic analysis of T-ALLs, and this has allowed mapping of cell-intrinsic genetic defaults in these cells to be expanded. However, much less is known about the potential cell-extrinsic cues that may impact on the leukemia genesis process, including the role that the TCR might play in malignant transformation throughout thymocyte selection, survival and proliferation. In this study, we sought to address how TCR signaling can interfere or, on the contrary, can be integrated in T-ALL oncogenic networks.

**Methods**

**Patients’ samples**

Diagnostic specimens (peripheral blood or bone marrow) collected from patients treated at the Timone Children’s Hospital or Paoli Calmettes Institute (Marseille, France) or from Necker Hospital (Paris, France) were used to generate xenografts. Diagnosis and classification were defined by expression of specific T-cell markers and negativity for B cells and myeloid markers. Healthy human thymus were obtained from Timone Children’s Hospital. Samples were purified by Ficoll-Hypaque centrifugation. T-ALLs were included within FRALLE-2000 or GRAALL-2005 protocols, and informed consent for use of diagnostic specimens for future research was obtained from the patients or relatives in accordance with the Declaration of Helsinki. This study was approved by institutional review boards of all hospitals involved.

**Mice**

Mice were bred and housed in specific pathogen-free conditions in CIML animal facilities and were handled in accordance with French and European guidelines. Mice strains and oligonucleotides used for mice genotyping are listed in the Online Supplementary Methods and Online Supplementary Table S1. Xenotransplantation of primary human T-ALL samples in immunodeficient NSG mice was performed as previously described.

**TCR-signaling ability assays**

TCR-signaling ability assays were performed with 2x10⁷ wild-
Type or leukemic cells resuspended in RPMI medium (200 μL) and stimulated for 2 minutes (min) at 37°C with avidin (14 μg) and biotinylated anti-CD3 (10 μg; clone 2C11, BD Pharmingen, for mouse cells and clone UCHT1, eBioscience for human cells) and biotinylated anti-CD28 (10 μg; clone 87.51, BD Pharmingen, for mouse cells and clone CD28.2, eBiosciences for human cells). Unstimulated (control) cells were incubated with avidin alone. After lysis in 2X TNE buffer (100 mM Tris, 2% Nonidet P-40, 40 mM EDTA) supplemented with protease and phosphatase inhibitors, protein extracts (approx. 60 μg) were analyzed by immunoblot (see Online Supplementary Methods and Online Supplementary Table S2). P-Tyr levels were quantified on the entire lane and normalized to ACTIN. P-AKT protein levels were normalized to AKT.

Proliferation and apoptosis assays following CD3/CD28 stimulation

For comparison of the TCR-signaling ability to mediate proliferation or apoptosis of normal or leukemic cells, 1.105 of non-purified or CD4 SP purified T cells were mixed (ratio 1:1) with Dynabeads Mouse T-Activator CD3/CD28 (Life Technologies) or Dynabeads Human T-Activator CD3/CD28 (Life Technologies) in 96-well flat bottom plates and incubated for 24 or 72 hours (h) (37°C, 5% CO2). For unstimulated controls, thymocytes were incubated in the same conditions but without anti-CD3/CD28 coated beads. Proliferation was measured using CFSE labeling (CellTrace™ CFSE Cell Proliferation Kit, Life Technologies) and apoptosis was followed using AnnexinV labeling (BD Pharmingen) and 7-AAD (BD Pharmingen) according to the manufacturer’s instructions.

Statistical analysis

Kaplan-Meier survival curves and statistical analyses were performed using GraphPad Prism software. Survival curves were compared using log-rank (Mantle-Cox) test. Statistical significance was evaluated by two-tailed Mann-Whitney U-test. P<0.05 was considered significant. Further details are provided in the Online Supplementary Methods and antibodies used for flow cytometry are listed in Online Supplementary Tables S3 and S4.

Results

Ptenαβ thymocytes expressing transgenic TCR are counter-selected during leukemogenesis

Phosphatase and tensin homolog protein (PTEN) is a well-known tumor suppressor involved in numerous types of cancers, and represents the main negative regulator of PI3K/AKT signaling pathway.12 To investigate the role of the TCR in leukemogenesis, we used a Pten-deficient mouse model of T-ALL which has previously been shown to induce TCRαβ+ tumors.13,14 PtenFlox/Flox mice were crossed into a CD4-Cre background (hereafter referred to as Ptenαβ) in which Cre is fully active at the CD4+CD8+ double positive (DP) stage of thymocyte development.15 As previously described,16 Ptenαβ mice developed leukemia characterized by malignant proliferation of mono/oligoclonal T cells (Online Supplementary Table S5), and enlarged thymus and spleen (Figure 1A). Peripheral leukemic blasts from Ptenαβ mice were typically CD4 SP and expressed αβTCR at their surface (Figure 1B and Online Supplementary Table S6), in line with previous reports.14,16,17 To analyze the impact of positive selection, we used the OT-II mouse model which expresses a transgenic Vα2/Vβ5.1 TCR recognizing the chicken ovalbumin antigen in the context of MHC-II molecules.18 Ptenαβ mice were crossed with OT-II Rag1-deficient mice, in which all developing T cells do express an OT-II fit TCR, designed to trigger positive selection and give rise to mature SP T

### Table 1. Immuno-phenotypes of T-cell acute lymphoblastic leukemia developed by OT-II x Ptenαβ mice in I-Aαβ or I-Aαβ backgrounds.

| Mouse # | I-Aαβ | CD4/CD8 | TCRαβ | TCR OT-II | TCRVβ | TCRVα |
|--------|-------|---------|-------|-----------|-------|-------|
| 25     | I-Aαβ | CD4+    | +     | Neg       | Vβ14  | Vα2  |
| 26     | I-Aαβ | CD4+DN  | +     | Neg       | Vβ11  | Vα2  |
| 28     | I-Aαβ | CD4     | +     | Neg       | Vβ14  | Vα2  |
| 70     | I-Aαβ | CD4+    | +     | Neg       | Vβ14  | Vα2  |
| 83     | I-Aαβ | CD4     | +     | Neg       | Vβ14  | Vα2  |
| 114    | I-Aαβ | CD4     | +     | Neg       | Vβ5   | Vα2  |
| 140    | I-Aαβ | CD4+DN  | +     | Neg       | Vβ8.1/8.2 | Vα2 |
| 141    | I-Aαβ | CD4+DN  | +     | Neg       | Vβ5   | Vα2  |
| 350    | I-Aαβ | CD4+    | +     | Neg       | Vβ14  | Vα2  |
| 2      | I-Aαβ | CD4+    | +     | +         | Vβ5   | Vα2  |
| 11     | I-Aαβ | CD4+    | +     | +         | Vβ5   | Vα2  |
| 12     | I-Aαβ | CD4+    | +     | +         | Vβ5   | Vα2  |
| 17     | I-Aαβ | CD4+    | +     | Neg       | Vβ5   | Vα2  |
| 19     | I-Aαβ | CD4+    | +     | +         | Vβ5   | Vα2  |
| 278    | I-Aαβ | CD4+    | +     | +         | Vβ5   | Vα2  |
| 281    | I-Aαβ | CD4+    | +     | +         | Vβ5   | Vα2  |
| 291    | I-Aαβ | CD4/DN  | +     | +         | Vβ5   | Vα2  |
| 321    | I-Aαβ | CD4/DN  | +     | +         | Vβ5   | Vα2  |
| 354    | I-Aαβ | CD4/DP  | +     | +         | Vβ5   | Vα2  |

*Negativity for TCRαβ and the TCRVβ expressed was not determined.
cells. Both [OT-II x Rag1<sup>−/−</sup> x Pten<sup>−/−</sup>] and the control TCR-deficient mice [Rag1<sup>−/−</sup> x Pten<sup>−/−</sup>] (Online Supplementary Figure S2) developed T-cell lymphoblastic lymphomas (T-LBL) which were mostly restricted to the thymus (Figure 1A), over-expressed Bcl2<sup>19</sup> and, as previously described,<sup>17</sup> were recurrently Notch1-dependent (Figure 1C). Indeed, we found that all [Rag1<sup>−/−</sup> x Pten<sup>−/−</sup>] tumors tested (n=7) and 3 out of 7 [OT-II x Rag1<sup>−/−</sup> x Pten<sup>−/−</sup>] tumors were Notch1 activated. Of note, Notch1 activation does not impact latency of [OT-II x Rag1<sup>−/−</sup> x Pten<sup>−/−</sup>] tumors (Online Supplementary Figure S3). Strikingly, in the [OT-II x Rag1<sup>−/−</sup> x Pten<sup>−/−</sup>] model, the examined tumors (n=15) had lost surface expression of the OT-II transgene and were either TCR<sup>αβ</sup>-<sup>−/−</sup> or TCR<sup>αβ</sup>low (Figure 1B), consistent with previous observations.<sup>17</sup> Molecular analysis of the transgenic β chain mRNA expression in the tumors revealed down-

**Figure 2.** Counter-selection of T cells harboring H-Y TCR. (A) Spleen (left) and thymus (right) of typical H-Y and tumoral [H-Y x Pten<sup>−/−</sup>] female mice. [H-Y x Pten<sup>−/−</sup>] mice developed T-cell acute lymphoblastic leukemias (T-ALL) in approximately ten weeks (n=5). (B) Flow cytometry analysis of typical spleens from H-Y and tumoral [H-Y x Pten<sup>−/−</sup>] female mice. (C) Flow cytometry analysis of typical disease-free thymus (left panels) and spleens (right panels) from young (4-week old) H-Y and [H-Y x Pten<sup>−/−</sup>] female mice. Percentages of cells in depicted gates are indicated. Representative data of at least 3 experiments are shown. Dot plots show percentages of CD8<sup>−/−</sup>SP, H-Y<sup>+</sup> CD8<sup>−/−</sup>SP or H-Y<sup>+</sup> DP thymic cells and H-Y<sup>+</sup> CD8<sup>−/−</sup> T cells from spleens of control H-Y (n= 7) and [H-Y x Pten<sup>−/−</sup>] (n=7) female mice. (D) Pre-tumoral single positive (SP) thymocytes are partially blocked at the immature CD69<sup>+</sup>CD62L<sup>−/−</sup> stage. Analysis of 4-week old disease-free (pre-tumoral) Pten<sup>−/−</sup> and [H-Y x Pten<sup>−/−</sup>] mice and their respective control counterparts is shown (representative data of at least 3 experiments), CD8<sup>+</sup>: mature CD8<sup>−/−</sup>SP (CD69<sup>−</sup>CD62L<sup>−</sup>); CD8<sup>−</sup>: immature CD8<sup>−/−</sup>SP (CD69<sup>−</sup>CD62L<sup>−</sup>). Arrows indicate the stage of differentiation arrest (SP2 and CD8 IM). Dot plots show percentages of CD4 SP2 and CD8 IM T cells in the indicated backgrounds (n=5 or 6). Error bars show means with Standard Deviation. Statistical significance was assessed using Mann-Whitney test (**P<0.01; ***P<0.001).
regulation of the Vβ5.1 transcript (Figure 1D). This suggests an active counter-selection of leukemic (or pre-leukemic) thymocytes bearing the transgenic TCR. The latency of tumor onset was significantly increased in [OT-II x Rag1+/− x Pten−/−] mice compared to Pten−/− mice, consistent with the time that is likely required for selection of TCRβ+ cells, while in the enforced absence of TCR ([Rag1−/− x Pten−/−] mice), latency was significantly reduced (Figure 1E), evoking a potential tumor suppressor role of TCR signaling in leukemogenesis.

To rule out transgenic-specific effect, we also tested the impact of selection in the H-Y mouse model, which expresses a transgenic TCR recognizing the male H-Y antigen in the context of MHC-I molecules. In female H-Y mice, negative selection is not operating, and positively selected mature H-Y TCR T cells differentiate as CD8 SP. H-Y mice were crossed with Pten−/− mice, on a Rag-proficient background to allow non-transgenic TCR competitive formation and development. [H-Y x Pten−/−] females developed TCRαβ+ T-ALL (Figure 2A and B). Remarkably, tumors were typically CD4 SP (never CD8 SP), and none of them expressed the transgenic H-Y TCR (Figure 2B). Thus, regardless of the model used, the expression by (pre-)tumoral thymocytes of a fit TCR is counter-selected during T-ALL development. In disease-free thymi and spleens of young female [H-Y x Pten−/−] mice (and thus before clinical tumor manifestation), we detected a severe reduction of H-Y+ TCR cells at the CD8 SP stage compared to control H-Y mice, and this was already apparent at the DP stage of thymocyte development (Figure 2C). In addition, this counter selection of H-Y+ thymocytes occurs post β-selection, after immature single positive (ISP) stage (Online Supplementary Figure S4).

These data suggest that Pten-deficient H-Y TCR thymocytes are eliminated instead of positively selected, and that this counter-selection occurs before full malignant transformation, preventing leukemia development.

**Disruption of final maturation of Pten-deficient SP cells**

Since most mature thymocytes with fit H-Y TCR are eliminated in young female disease-free [H-Y x Pten−/−] mice, we analyzed the remaining H-Y TCR negative SP cells, using the CD69, CD62L and CCR9 markers of T-cell differentiation. Developmental sequence of CD4 SP thymocyte maturation is usually described as SP1 (CD69+, CD62Lmed, CCR9+), SP2 (CD69+, CD62Llow, CCR9neg) and SP3 (CD69neg, CD62Lhigh, CCR9neg). For CD8 SP cells, the most immature cells are CD69+ and CD62Lhigh while the more mature are CD69neg and CD62Llow. We observed for both [H-Y x Pten−/−] and Pten−/− models a partial block of positively selected cells at the immature CD69+CD26low stage (Figure 2D). Such differentiation arrest could provide an additional opportunity for malignant transformation.

**Fit TCR signaling acts as a tumor suppressor**

With the premise that Pten-deficient cells with fit TCR are counter-selected, we next assessed whether cells carrying low affinity (unfit) TCR were prone to leukemia development. OT-II TCR originates from CD4+ I-Ab-restricted T-cell hybridoma, thus positive selection is optimal in I-Aββ background and sub-optimal in I-Aβd background. C57BL/6 (I-Aβ) [OT-II x Pten−/−] mice were crossed with BALB/C (I-Aβ) mice to generate Rag-proficient [OT-II x Pten−/−] mice on I-Aβd background. OT-II control mice, percentages of CD4+ T cells dropped from approximately 78% in syngeneic I-Aββ background to approximately 7% in allogenic I-Aβd background (Figure 3A). [OT-II x Pten−/−] Rag-proficient mice developed T-ALL with a similar latency as Pten−/− mice (approx. 11 weeks), irrespective of the backgrounds (I-Aββ or I-Aβd). Leukemic blasts in the spleen were mostly CD4+ (Table 1). On the I-Aβd background, while all T-ALL analyzed (n=9) expressed a TCRαβ, none of them...
expressed the full transgenic OT-II TCR (usually TCRVα2 chain was expressed, but not associated with TCRVβ5 chain) (Table 1 and Figure 3). In line with the H-Y model above, this indicates that (pre)leukemic clones harboring OT-II fit TCR are counter-selected during oncogenesis. In striking contrast, most of TCRαβ+ T-ALL in the allogenic I-Aκβ background (9 of 10) expressed OT-II (Table 1 and Figure 3A). This indicates that in a context of sub-optimal positive selection, Pten−/− OT-II blasts are not counter-selected, but rather bypass death-by-neglect during positive selection allowing further leukemia development.

Altogether our data indicate that, in Pten-deficient T-ALL mouse models, fit TCR functions as a tumor suppressor impeding thymocytes to develop leukemia, while thymocytes expressing no or unfit TCR are prone to leukemogenesis.

**TCRαβ signaling is disabled in Pten-deficient T-ALL**

We next asked whether endogenous TCRαβ+ from Pten−/− mice, which presumably passed positive selection...
and developed T-ALL, acquired a deficiency in TCR signaling. Unstimulated primary mouse T-ALLs tend to quickly undergo apoptosis in liquid culture in vitro and can be rescued through anti-CD3/anti-CD28 TCR activation, as shown for the TCRαβ+ Cdkn2a− T-ALL mouse model (Figure 4A, Online Supplementary Table S6 and Online Supplementary Figures S5 and S6A). By contrast, no rescue could be obtained for T-ALL blasts from the Pten−/− T-ALL model, and TCRαβ+ Pten−/− leukemic cells quickly died with or without stimulation. To further investigate the impact of TCR triggering at the molecular level, freshly harvested tumors were CD3/CD28 stimulated for 2 min and analyzed by immunoblotting with antibodies specific for phosphorylated tyrosine species (P-Tyr) (Figure 4B). In control purified DP and non-purified (NP) mouse WT thymocytes, activation of the TCR pathway triggered various intracellular signaling molecules25 leading to a marked increase in the pattern of global tyrosine phosphorylation (Figure 4B and C), as previously described.24 Similar results were obtained with Cdkn2a− T-ALLs, in line with proliferation data described above. By contrast, global tyrosine phosphorylation was significantly dampened in murine TCRαβ+ Pten−/− T-ALLs (Figure 4B and C). However, P-Tyr antibody does not detect the activation of AKT which is the main downstream target of Pten.12 Thus, we specifically monitored phosphorylation of Akt at Ser473. It was previously showed that Akt phosphorylation was very high in non-tumoral Pten-deficient thymocytes compared to Pten-proficient thymocytes.13 However, we found that P-Akt levels in Pten−/− T-ALL are similar to the one detected for WT thymocytes and Cdkn2a− T-ALL (Figure 4B and C) and thus are lower than one might expect from Pten-deficient thymocytes.13

It is noteworthy that when we induced inactivation of Pten in Cdkn2a− T-ALL cells, the ability of those cells to proliferate upon stimulation was conserved (Online Supplementary Figure S7), suggesting that once pre-tumoral thymocytes have passed selection and the tumor is established, late deletion of Pten no longer interferes with TCR-mediated activation. In the same line, T cells from disease-free Pten−/− spleen were able to proliferate upon anti-CD3/28 stimulation (Online Supplementary Figure S8), confirming that, per se, Pten loss is not directly responsible for the TCR signaling inhibition observed in Pten−/− T-ALL. Together with the fact that human late cortical T-ALLs are frequently carrying Pten loss-of-function alterations,3 this pointed to a possible role of Pten loss in the dysregulation of the selection process. We thus assessed whether the above observation indicating that TCR signaling is impaired in Pten-deficient T-ALL was relevant in human primary T-ALL samples. To obtain adequate quantities of viable human leukemia cells devoid of contaminating residual physiological mature T cells, samples from T-ALL patients were engrafted into immunodeficient NSG mice. In our patient-derived xenograft (PDX) collection, Pten was present in all TCRneg T-ALL, while it was not expressed in 5 out of 6 TCRαβ+ samples. We investigated the 5 Pten-deficient TCRαβ+ T-ALL (T-ALL 8, 9, 35, 38 and 47; their corresponding xenografts were denoted Xg8, Xg9, Xg35, Xg38 and Xg47), and 5 TCRneg T-ALLs were used as controls (Xg3, Xg13, Xg20, Xg23 and Xg40) (Online Supplementary Table S7 and Online Supplementary Figure S6B). Leukemic grafts were harvested from mice and stimulated with anti-CD3 and anti-CD28. In contrast to mouse, human T-ALL do not do die quickly in liquid culture; thus we assessed the impact of TCR stimulation at the cellular level. We observed that activation-induced cell death (AICD) was triggered for only 1 TCRαβ+ T-ALL (Xg3), the remaining 4 TCRαβ+ T-ALL, as well as control TCRneg T-ALLs, being resistant to AICD (Figure 4D and E). To investigate signaling downstream of the TCR, as described above for mouse T-ALL, PDX cells were lysed 2 min post activation with anti-CD3/CD28, and analyzed by immunoblotting. In control (disease-free) non-purified (NP) or purified CD4 SP human thymocytes, activation of the TCR pathway led to a marked increase in the pattern of global tyrosine phosphorylation. In contrast, the TCRαβ+ T-ALL samples showed a reduced and somewhat intermediate activation of tyrosine phosphorylated species compared to NP or CD4 SP positive control (Figure 4B and C). However, we found that P-Akt levels in Pten−/− T-ALL are similar to the one detected for WT thymocytes and Cdkn2a− T-ALL (Figure 4B and C) and thus are lower than one might expect from Pten-deficient thymocytes.13

Figure 5. Model for integration of Pten loss-of-function and TCR signaling-mediated tumor suppression. In the context of Pten loss, thymocytes bearing fit or high affinity TCR would be eliminated while those bearing no/low affinity TCR would be rescued from death-by-neglect. However, harboring TCR complex that does not signal properly would prevent further thymocyte differentiation, providing an additional opportunity for malignant transformation.
Taken together, these data indicate that both in mouse and human, TCRαβ signaling network is largely disabled in PTEN-deficient TCRαβ+ T-ALLs.

Discussion

Here we undertook to investigate the impact of TCR signaling during T-ALL leukemogenesis. We show that in a mouse model of Pten loss-of-function, a frequent event among human TCRαβ+ T-ALLs (approx. 70%) (Online Supplementary Table S8), early counter-selection of fit TCRαβ+ thymocytes, occurs before the onset of leukemia development. Furthermore, we show that established TCRαβ+ T-ALLs are carrying TCRs which are unfit and/or impaired in signaling.

T-ALLs represent the malignant counterparts of most thymocyte stages of development. Analysis of T-ALL subtype distribution based on a human T-ALL cohort of 230 subjects showed that early immature (n=52), cortical T-ALL (n=103), mature TCRγδ+ T-ALL (n=56) and mature TCRαβ+ T-ALL (n=39) represent 22.6%, 44.8%, 15.6% and 17%, respectively, of T-ALL cases. Intriguingly, among the TCRgδ+ T-ALL, TCRαβ+ T-ALLs were under-represented (52%) relative to TCRγδ+ (45%) compared to physiological counterparts in which TCRαβ+ largely dominate the fraction of TCRgδ+ thymocytes (approx. 95% vs. approx. 5% TCRγδ).26 Unlike αβ T cells, γδ T cells are not restrained to MHC and do not undergo conventional MHC-mediated positive and negative selections.26,27 Conversely to pre-tumoral αβ T cells, pre-tumoral γδ T cells might thus not be counter-selected, possibly explaining their over-representation compared to TCRαβ+ T-ALL.

Our in vivo data showed that pre-tumoral Pten+/− cells with unfit TCR signaling (OT-II in I-Aκ background) are positively selected for leukemogenesis, while thymocytes with fit TCR signaling (H-Y or OT-II in I-Aκ background) are counter-selected and never developed leukemia. Thus this study points to a role of Pten during the positive selection process. Yet the specific molecular mechanism allowing positive selection of pre-tumoral cells with unfit TCR (and counter-selection of cells with fit TCR) in the absence of Pten remains to be determined. A possible scenario would be that Pten loss merely shifts the window of positive and negative selection thresholds (Figure 5). On one hand, Pten loss might substitute for missing TCR signaling, allowing cells with no TCR or low affinity TCR to be rescued from death by neglect and bypass positive selection. Accordingly, an increase in positively selected T cells was observed in mouse models in which AKT was hyperactive.28 Herein, we found that, following TCR-stimulation, AKT activation is similar in Pten-deficient T-ALL and in WT thymocytes. Therefore, while most of the TCR signaling network is disabled (Figure 4), AKT pathway appears ‘normal’ and, in the context of our scenario (Figure 5), is likely to be the main element contributing to the bypass of positive selection by Pten-deficient thymocytes harboring unfit/low TCR. On the other hand, integration of signals resulting from both Pten loss and a fit TCR (passing positive selection) might reach over-the-threshold signaling and trigger negative selection, eliminating thymocytes carrying fit TCRs even before malignant transformation. This would involve multiple pathways downstream of Pten loss,29 since a mere AKT hyperactivation was insufficient to recapitulate the loss of fit H-Y thymocytes.29 A challenging perspective would be to decipher the molecular mechanism underlying the counter-selection of Pten-deficient fit αβ TCR thymocytes and then to assess the possibility of activating this apoptotic program in tumoral cells.

Our data indicate that TCRαβ signaling pathway is actively involved in T-ALL oncogenesis. We show that TCRαβ signaling can impede the development of Pten-deficient tumors and thus acts as a bona fide tumor suppressor. However, given the diametrically opposed effect of TCR activation on discrete stages of T-cell development, the TCR might also have pro-oncogenic effects in other contexts and/or developmental stages. For example, we show that in a Pten-proficient Cdkn2a−/− T-ALL model, TCRαβ+ tumors are sensitive to TCR activation. Likewise, thymocytes harboring fit H-Y TCR are not counter-selected in female TEL-JAK2 mouse model and develop leukemia.21 In the same line, Pten-deficient TCRα−/− or SLP76−/− mice, in which TCR signaling is abrogated, display delayed tumor onset.21 Yet, and in contrast to the Pten−/− model, TCRα−/− and SLP76−/− thymocytes are blocked before (and therefore not subjected to) positive selection.30,31 Pre-TCR might also be directly involved in oncogenesis. For instance, in dominant active NOTCH1 (ICN1) model, pre-TCR signaling is required for tumorigenesis.32 Conversely [Rag1−/− x Pten−/−] thymocytes that are devoid of pre-TCR bypass β-selection and develop DP T-cell lymphoma in short latency (Figure 1); this is also in striking contrast to Pten-deficient TCRα−/− or SLP76−/− thymocytes (described above) that express a pre-TCR and for which leukemogenesis is impaired.17 In normal β-selected cells, the exit of proliferation is induced by pre-TCR signals that inhibit Notch1 pathway leading to Myc downregulation.33,34 In [Rag1−/− x Pten−/−] DP lymphoma, Notch1 pathway is systematically activated leading to sustained expression of Myc (Figure 1C) it might be that pre-TCR signaling exerts a tumor suppressor role by shutting down Notch1 and Myc pathways.

A recent study indicated that TCRαβ+ T-ALL were prone to activation-induced cell death (AICD), and anti-CD8 stimulation of TCR signaling was proposed as a therapeutic strategy to eliminate leukemic blasts.35 By contrast, most of our TCRαβ+ T-ALL samples (4 of 5) were resistant to AICD (Figure 4E). This discrepancy could be due to the stage of arrest (before or after positive/negative selections) of T-ALL samples, as in both studies sensitive TCRαβ+ samples (4 of 5 in the in vivo analysis of Trinquand et al.36 and 1 of 5 in our study) were CD1a+, consistent with an arrest at cortical DP stage, during which positive and negative selections occur.37 In contrast, AICD-resistant samples in both studies represented true late-cortical CD1a+SP T-ALLs. This cautions that anti-CD8 therapeutic strategies might be restrained to a subgroup of sensitive TCR-αβ T-ALL (such as TCRαβ+CD1a−, eventually the rare TCRαβ+PTEN+ cases, or TCRαβ−), and thus for mature TCRαβ+PTEN− T-ALL alternative options should be considered. Here we have showed that integration of Pten loss and fit TCR signaling promotes a deletional program. Thus, an attractive perspective would be to decipher the mechanism underlying this apoptotic program in order to uncover an actionable target inducing cell-death, which might open new therapeutic avenues for this poor prognosis PTEN-deficient TCRαβ subgroup.38
References

1. Klein I, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol. 2014;14(6):377-391.

2. Assaad V, Bedford K, Boulanger E, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003;101(7):2693-2703.

3. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol. 2003;40(4):274-282.

4. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106(1):274-286.

5. Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukemia. Nat Rev Cancer. 2016;16(8):494-507.

6. Dadi S, Le Noir S, Payet-Bornet D, et al. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2016;29(5):972-985.

7. Cui Y, Onozawa M, Garber HR, et al. FTEN: Multiple Functions in Human Malignant Tumors. Front Oncol. 2015;5:24.

8. Newton RH, Lu Y, Papa A, et al. Suppression of T-cell lymphomagenesis in mice requires FTEN phosphatase activity. Blood. 2015;125(5):853-859.

9. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 2001;14(5):523-534.

10. Na SY, Patra A, Scheuring Y, et al. Constitutively active protein kinase B enhances Lck and Erk activities and influences thymocyte selection and activation. J Immunol. 2005;171(3):1285-1296.

11. Milella M, Falcone I, Conciantoni F, et al. T-ALL: Multiple Functions in Human Malignant Tumors. Front Oncol. 2015;5:24.

12. Newton RH, Le Noir S, Payer-Bornet D, et al. TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRAp3 gene expression. Cancer Cell. 2012;21(4):454-468.

13. Chien YH, Meyer C, Bonneville M. gammadealta T cells: first line of defense and beyond. Annu Rev Immunol. 2014;32:121-155.

14. Newton RH, Huang Y, Reinhardt RL, Huang H, Sun D, O’Brien RL. gammadealta T Cells and B Cells. Adv Immunol. 2017;134:1-45.

15. Na SY, Patra A, Scheuring Y, et al. Constitutively active protein kinase B enhances Lck and Erk activities and influences thymocyte selection and activation. J Immunol. 2005;171(3):1285-1296.

16. Kisielow P, Teh HS, Bluthmann H, von Boehmer H. Positive selection of antigen-specific T cells in thymus by restricting MHC molecules. Nature. 1988;335(6192):730-733.

17. Feng H, Stachura DL, White RM, et al. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus leukemia. 2008;22(3):609-619.

18. Liu X, Karnell JL, Yin B, et al. Distinct roles for FTEN in prevention of T cell lymphoma and autoimmunity in mice. J Clin Invest. 2010;120(7):2497-2507.

19. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha and beta-chain genes up the control of heterologous regulatory elements. Immunol Cell Biol. 1998;76(1):34-40.

20. Hagenbeek T, Spits H. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus leukemia. 2008;22(3):609-619.

21. Poltorak M, Arndt B, Kowtharapu BS, et al. Directly measured alpha and beta block thymocyte development at different stages. Nature. 1998;395(6701):1285-1296.

22. Mombaerts P, Clarke AR, Rudnicki MA, et al. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature. 1998;395(6701):1285-1296.

23. Allman D, Karnell FG, Punt JA, et al. Separation of Notch1 promoted lineage commitment and expansion/transformation in developing T cells. J Exp Med. 2001;194(1):99-106.

24. Mombaerts P, Clarke AR, Rudnicki MA, et al. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature. 1998;395(6701):1285-1296.

25. Mombaerts P, Clarke AR, Rudnicki MA, et al. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature. 1998;395(6701):1285-1296.

26. Mombaerts P, Clarke AR, Rudnicki MA, et al. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature. 1998;395(6701):1285-1296.

27. Mombaerts P, Clarke AR, Rudnicki MA, et al. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature. 1998;395(6701):1285-1296.

28. Mombaerts P, Clarke AR, Rudnicki MA, et al. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature. 1998;395(6701):1285-1296.

29. Mombaerts P, Clarke AR, Rudnicki MA, et al. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature. 1998;395(6701):1285-1296.

Acknowledgments

The authors thank the European Mouse Mutant Archives (EMMA) for providing Ptenflox/flox mice, Charles Pignon and Maeva Patry for mouse genotyping, Virginique Foulquier (Cardiac Surgery Department, APHM, Marseille, France) for providing human thymus, Marie Malissen for providing CD4-Cre and H2Y mice, the CRMC cytometry platform for phosphoflow FACS analysis and Philippe Naquet for the critical reading of the manuscript.